Bioventus (BVS)
(Delayed Data from NSDQ)
$6.55 USD
-0.03 (-0.46%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $6.56 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BVS 6.55 -0.03(-0.46%)
Will BVS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BVS
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
Encompass Health (EHC) Expands in Louisville With New Rehab Unit
BVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Investors Must Hold on to Centene (CNC) Stock Now
Compelling Reasons to Hold on to Cigna (CI) Stock for Now
Here's Why You Should Consider Buying Bioventus (BVS) Stock
Other News for BVS
Envoy Medical appoints Michael Crowe to board of directors
Bravura Joins S&P/ASX Tech Index in June Rebalance
3 Stocks Under $10 With Mammoth Growth Prospects
Bioventus management to meet with Craig Hallum
Bioventus: Poised for Growth Amidst Strategic Refinement and Debt Reduction